Stock listing
ASX:RHY Rhythm Biosciences Limited Share Price
Home listing (ASX) of Rhythm Biosciences Limited
Follow Rhythm Biosciences Limited into a list and get an email when it puts out news.
Share price · ASX:RHY
$0.06 AUD -0.00 (-1.6%)
Close on Nov 20, 2026
- Day range
- $0.06 – $0.06 AUDNov 20, 2026
- Volume
- 30,924 sharesNov 20, 2026
- Market cap
- $21.23M AUDAt the close on Nov 20, 2026 · price × 353.9M shares outstanding
- 52-week range
- $0.06 – $0.28 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $15,659 AUDMedian day 93,119 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:RHY · Home | $0.06 AUD | -0.001 (-1.6%) | 30,924 | $0.06 | $0.06 | $0.06 | $0.061 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:RHY · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.06 | -0.001 | -1.6% | $0.06 | $0.06 | $0.06 | 30,924 | |
| $0.061 | 0.00 | 0.0% | $0.061 | $0.061 | $0.061 | 13,530 | |
| $0.061 | -0.002 | -3.2% | $0.064 | $0.065 | $0.061 | 33,609 | |
| $0.063 | -0.003 | -4.5% | $0.066 | $0.066 | $0.062 | 1,146,494 | |
| $0.066 | 0.00 | 0.0% | $0.067 | $0.067 | $0.066 | 102,025 | |
| $0.066 | +0.001 | +1.5% | $0.065 | $0.066 | $0.064 | 36,793 | |
| $0.065 | -0.002 | -3.0% | $0.067 | $0.067 | $0.065 | 133,743 | |
| $0.067 | -0.002 | -2.9% | $0.067 | $0.067 | $0.067 | 66,312 | |
| $0.069 | 0.00 | 0.0% | $0.067 | $0.069 | $0.067 | 22,777 | |
| $0.069 | -0.001 | -1.4% | $0.069 | $0.072 | $0.068 | 80,339 | |
| $0.07 | +0.007 | +11.1% | $0.068 | $0.07 | $0.065 | 171,086 | |
| $0.063 | 0.00 | 0.0% | $0.063 | $0.063 | $0.063 | 0 | |
| $0.063 | 0.00 | 0.0% | $0.062 | $0.063 | $0.062 | 15,433 | |
| $0.063 | 0.00 | 0.0% | $0.063 | $0.063 | $0.063 | 35,843 | |
| $0.063 | 0.00 | 0.0% | $0.063 | $0.064 | $0.062 | 90,835 | |
| $0.063 | -0.002 | -3.1% | $0.066 | $0.066 | $0.063 | 32,853 | |
| $0.065 | 0.00 | 0.0% | $0.066 | $0.066 | $0.065 | 127,191 | |
| $0.065 | 0.00 | 0.0% | $0.065 | $0.065 | $0.065 | 0 | |
| $0.065 | -0.003 | -4.4% | $0.068 | $0.068 | $0.065 | 38,946 | |
| $0.068 | +0.001 | +1.5% | $0.068 | $0.068 | $0.068 | 12,172 | |
| $0.067 | 0.00 | 0.0% | $0.067 | $0.067 | $0.067 | 6,090 | |
| $0.067 | 0.00 | 0.0% | $0.069 | $0.069 | $0.067 | 93,479 | |
| $0.067 | -0.003 | -4.3% | $0.07 | $0.071 | $0.067 | 121,954 | |
| $0.07 | +0.001 | +1.4% | $0.069 | $0.07 | $0.067 | 238,639 | |
| $0.069 | +0.002 | +3.0% | $0.061 | $0.069 | $0.06 | 824,369 | |
| $0.067 | -0.001 | -1.5% | $0.068 | $0.068 | $0.067 | 212,364 | |
| $0.068 | -0.002 | -2.9% | $0.07 | $0.07 | $0.068 | 77,226 | |
| $0.07 | -0.006 | -7.9% | $0.073 | $0.073 | $0.07 | 304,511 | |
| $0.076 | +0.001 | +1.3% | $0.075 | $0.076 | $0.074 | 60,064 | |
| $0.075 | +0.003 | +4.2% | $0.072 | $0.077 | $0.072 | 216,340 | |
| $0.072 | -0.004 | -5.3% | $0.078 | $0.078 | $0.071 | 264,411 | |
| $0.076 | -0.002 | -2.6% | $0.078 | $0.08 | $0.076 | 332,420 | |
| $0.078 | -0.002 | -1.9% | $0.079 | $0.079 | $0.077 | 176,881 | |
| $0.08 | -0.001 | -0.6% | $0.08 | $0.08 | $0.077 | 46,928 | |
| $0.08 | -0.001 | -1.2% | $0.076 | $0.08 | $0.076 | 15,558 | |
| $0.081 | 0.00 | 0.0% | $0.081 | $0.081 | $0.08 | 127,186 | |
| $0.081 | 0.00 | 0.0% | $0.081 | $0.081 | $0.08 | 1,014,505 | |
| $0.081 | -0.002 | -2.4% | $0.083 | $0.083 | $0.081 | 421,860 | |
| $0.083 | +0.001 | +1.2% | $0.082 | $0.083 | $0.082 | 9,127 | |
| $0.082 | 0.00 | 0.0% | $0.082 | $0.083 | $0.082 | 22,558 | |
| $0.082 | 0.00 | 0.0% | $0.082 | $0.083 | $0.082 | 143,224 | |
| $0.082 | +0.001 | +1.2% | $0.084 | $0.084 | $0.082 | 242,303 | |
| $0.081 | -0.001 | -1.2% | $0.082 | $0.087 | $0.081 | 1,240,395 | |
| $0.082 | 0.00 | 0.0% | $0.083 | $0.083 | $0.081 | 220,482 | |
| $0.082 | 0.00 | 0.0% | $0.08 | $0.082 | $0.08 | 22,105 | |
| $0.082 | +0.002 | +2.5% | $0.081 | $0.082 | $0.08 | 33,670 | |
| $0.08 | 0.00 | 0.0% | $0.08 | $0.081 | $0.08 | 51,808 | |
| $0.08 | -0.002 | -2.4% | $0.082 | $0.082 | $0.08 | 259,442 | |
| $0.082 | -0.001 | -1.2% | $0.082 | $0.082 | $0.082 | 63,970 | |
| $0.083 | -0.004 | -4.6% | $0.093 | $0.093 | $0.083 | 303,147 | |
| $0.087 | +0.005 | +6.1% | $0.085 | $0.089 | $0.085 | 128,325 | |
| $0.082 | 0.00 | 0.0% | $0.082 | $0.082 | $0.082 | 13,242 | |
| $0.082 | -0.003 | -3.5% | $0.085 | $0.085 | $0.082 | 253,634 | |
| $0.085 | -0.002 | -2.3% | $0.084 | $0.086 | $0.084 | 86,883 | |
| $0.087 | +0.002 | +2.4% | $0.086 | $0.088 | $0.084 | 92,759 | |
| $0.085 | -0.004 | -4.5% | $0.091 | $0.091 | $0.085 | 36,209 | |
| $0.089 | -0.005 | -5.3% | $0.093 | $0.093 | $0.086 | 461,265 | |
| $0.094 | +0.007 | +8.0% | $0.09 | $0.094 | $0.09 | 10,179 | |
| $0.087 | -0.01 | -10.3% | $0.096 | $0.096 | $0.087 | 546,322 | |
| $0.097 | -0.001 | -1.0% | $0.099 | $0.10 | $0.097 | 128,532 | |
| $0.098 | -0.001 | -1.0% | $0.105 | $0.105 | $0.098 | 230,346 | |
| $0.099 | -0.006 | -5.7% | $0.10 | $0.103 | $0.097 | 281,526 | |
| $0.105 | +0.017 | +19.3% | $0.093 | $0.105 | $0.091 | 1,019,920 | |
| $0.088 | 0.00 | 0.0% | $0.088 | $0.09 | $0.088 | 22,461 | |
| $0.088 | +0.001 | +1.1% | $0.087 | $0.092 | $0.087 | 288,980 | |
| $0.087 | +0.005 | +6.1% | $0.087 | $0.087 | $0.087 | 18,219 |
- Ticker
- ASX:RHY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 16, 2026
Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer
Latest deck · Nov 4, 2026
Q1 FY27 Earnings Presentation
Earnings · 18 slides
Latest news
Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer
Nov 16, 2026
Closed $0.061 (-3.2%) on Nov 17, 2026
Commercial Update-Expansion of ColoSTAT ordering capability
Nov 4, 2026
Closed $0.07 (+11.1%) on Nov 5, 2026
RHY Q1 FY27 Update
Nov 3, 2026
Closed $0.063 (0.0%) on Nov 4, 2026
Quarterly Activities Report and Appendix 4C
Oct 26, 2026
Closed $0.065 (0.0%) on Oct 27, 2026
Notice of Annual General Meeting/Proxy Form
Oct 26, 2026
Closed $0.065 (0.0%) on Oct 27, 2026
ColoSTAT Economic Study - Australian Public Health Savings
Oct 6, 2026
Closed $0.076 (-2.6%) on Oct 7, 2026
Final Director's Interest Notice - Gavin Fox-Smith
Sep 30, 2026
Closed $0.081 (0.0%) on Oct 1, 2026
FY26 Appendix 4G and Corporate Governance Statement
Sep 29, 2026
Closed $0.081 (0.0%) on Sep 30, 2026
FY26 Annual Report
Sep 29, 2026
Closed $0.081 (0.0%) on Sep 30, 2026
AGM date and closing date for director nominations
Sep 28, 2026
Closed $0.081 (-2.4%) on Sep 29, 2026
Rhythm Biosciences Limited on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 34 in the last 12 months · 183 in all · newest Nov 16, 2026 · oldest 2017
- Decks
- 46 decks · latest Nov 4, 2026
Where Rhythm Biosciences Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:RHY · Home listing · This page | ASX | Australia | AUD |
| Frankfurt:0RY | Frankfurt | Germany | EUR |
Valuation
EV/sales 211× against a median of 1.8×: the highest of 11 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $18.04M AUD
- P/E
- Loss
- EV/sales
- 211×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.8×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rhythm Biosciences Limited · ASX:RHY | US$14.05M | US$11.94M | n/a | 211× | n/a | 5.8× | n/a | 0.1× | n/a |
| PlexBio Co., Ltd. · TPEX:6572 | US$15.79M | US$7.19M | n/a | 1.9× | n/a | 1.8× | −49.1% | 0.0× | n/a |
| Biosynex SA · EURONEXT:ALBIO | US$15.37M | US$73.75M | n/a | 0.7× | 2.3× | 0.4× | −61.1% | 1.9× | n/a |
| Verici DX PLC · LSE:VRCI | US$15.25M | US$13.61M | n/a | 3.6× | n/a | 2.6× | −189.2% | 0.1× | n/a |
| Medicon Hellas · ATHEX:MEDIC | US$14.99M | US$7.66M | 7.7× | 0.4× | 1.9× | 0.7× | 9.8% | 0.0× | n/a |
| Pharmigene, Inc. · TPEX:7595 | US$14.70M | US$29.38M | n/a | 4.8× | n/a | 1.9× | −36.5% | 2.2× | n/a |
| BCAL Diagnostics Limited · ASX:BDX | US$14.64M | US$18.17M | n/a | 150× | n/a | n/a | n/a | n/a | n/a |
| Noul Co Ltd. · KRX:376930 | US$14.03M | US$6.23M | n/a | 1.6× | n/a | 1.1× | −389.6% | 0.0× | n/a |
| Telescope Innovations Corp · CSE:TELI | US$13.52M | US$12.59M | n/a | 2.5× | n/a | 5.7× | −56.0% | 0.0× | 1.20 |
| LabGenomics Co., Ltd. · KRX:084650 | US$13.28M | US$2.59M | n/a | 0.0× | n/a | 0.1× | −66.5% | 0.1× | n/a |
| IDT Australia Limited · ASX:IDT | US$13.09M | US$18.52M | n/a | 1.4× | n/a | 1.0× | −13.4% | 0.6× | n/a |
| Median of the others | US$14.67M | US$13.10M | 7.7× | 1.8× | 2.0× | 1.1× | −56.0% | 0.1× | 1.20 |
Team and board
Officers
| Officer | Role |
|---|---|
| David Atkins | Chief Executive Officer & Managing Director |
| Andrea Steele | Legal Counsel |
| Adam Zembrzuski | Chief Commercial Officer |
| Erika Spaeth | Director of Clinical & Scientific Affairs |
| Gary Goh | Director of Operations and Quality |
Board
| Director | Role |
|---|---|
| Sue MacLeman BPharm LLM MMktg FTSE | Non-Executive Interim Chair |
| Carl Stubbings | Non-Executive Director |
| Maureen Baker | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Feb 18, 2026 | +2.4% |
| Q4 2025 | Aug 29, 2025 | −9.0% |
| Q2 2025 | Feb 20, 2025 | −1.0% |
| Q2 2023 | Feb 23, 2023 · After close | +3.7% |
| Q4 2022 | Aug 29, 2022 · After close | −1.5% |
| Q2 2022 | Feb 24, 2022 · After close | +1.9% |
| Q4 2021 | Aug 31, 2021 | +1.6% |
| Q2 2021 | Feb 24, 2021 | +4.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 FY27 Earnings Presentation | Earnings | 18 slides | Nov 4, 2026 |
| 20th Bioshares Biotech Summit 2026 | Conference | 15 slides | Aug 6, 2026 |
| Accreditation Matters Conference 2026 | Conference | 15 slides | Jul 7, 2026 |
| Investor Presentation (June 2026) | Investor deck | 19 slides | Jun 4, 2026 |
| Corporate Update (May 2026) | Corporate update | 9 slides | May 13, 2026 |
| Investor Presentation (March 2026) | Investor deck | 14 slides | Mar 18, 2026 |
| Investor Presentation (February 2026) | Investor deck | 19 slides | Feb 16, 2026 |
| Invest & Connect Event (November 2025) | Conference | 4 slides | Nov 26, 2025 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 15 slides | Nov 5, 2025 |
| Non-Deal Roadshow (October 2025) | Roadshow | 21 slides | Oct 10, 2025 |
All 46 decks
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.3K | 3.19M | 1.69M | 3.10M | 2.43M | 1.11M | 100.0K | 1.03M | 64.5K | 0 |
| Cost of revenue | 4.48M | 224.9K | 3.05M | 189.4K | 101.5K | 146.6K | 141.3K | 65.4K | 31.5K | 0 |
| Gross profit | -4.40M | 2.97M | -1.36M | 2.91M | -101.5K | 961.9K | -41.3K | 962.3K | -31.5K | 0 |
| Research and development | 1.04M | 1.38M | 2.35M | 3.65M | 5.16M | 4.55M | 1.94M | 980.3K | 359.1K | 299.5K |
| Selling, general and administrative | 5.95M | 1.67M | 1.41M | 7.33M | 5.33M | 2.97M | 2.00M | 2.28M | 1.13M | 422.0K |
| Operating income | -7.46M | -3.53M | -6.71M | -11.5M | -8.72M | -6.48M | -3.92M | -3.71M | -1.60M | -72.1K |
| Depreciation and amortization | 189.3K | 196.9K | 198.7K | 189.4K | 101.5K | 146.6K | 141.3K | 65.4K | 31.5K | 805.5K |
| EBITDA | -7.27M | -3.34M | -6.51M | -11.4M | -8.62M | -6.33M | -3.78M | -3.65M | -1.57M | 733.4K |
| Interest expense | 74.8K | 66.7K | 3.14K | 25.0K | 396 | 7.80K | 0 | 0 | 0 | |
| Income before tax | -7.51M | -3.83M | -8.55M | -8.22M | -8.79M | -6.61M | -4.02M | -2.55M | -1.75M | -866.0K |
| Income tax | -1.58M | -1.69M | -228.0K | -2.41M | 1.11M | 107.8K | -1.17M | 124.8K | -806.0K | |
| Net income | -5.93M | -3.83M | -6.86M | -8.22M | -8.79M | -6.61M | -4.02M | -2.55M | -1.75M | -72.1K |
| Earnings per share, basic | -0.02 | -0.01 | -0.03 | -0.04 | -0.04 | -0.04 | -0.03 | -0.02 | -0.02 | -0.00 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.36M | 1.40M | 709.5K | 4.12M | 7.55M | 2.23M | 1.80M | 4.73M | 7.78M | 1.49M |
| Short-term investments | 85.0K | 85.0K | 45.0K | 45.0K | 45.0K | 45.0K | 45.0K | 45.0K | 45.0K | |
| Receivables | 64.3K | 61.9K | 37.2K | 65.5K | 82.4K | 164.0K | 139.2K | 797.7K | 35.2K | 4.37K |
| Inventory | 16.3K | 74.4K | 57.8K | 2.77M | -1.00K | |||||
| Current assets | 3.76M | 1.81M | 886.7K | 7.12M | 7.77M | 2.49M | 2.01M | 5.61M | 7.87M | 1.50M |
| Property, plant and equipment | 171.0K | 113.2K | 104.9K | 240.7K | 113.8K | 142.6K | 90.2K | 9.30K | ||
| Goodwill | 531.0K | 531.0K | ||||||||
| Total assets | 4.78M | 2.83M | 1.52M | 7.70M | 8.44M | 3.07M | 2.65M | 6.23M | 8.45M | 1.55M |
| Accounts payable | 332.9K | 529.6K | 211.6K | 1.33M | 278.3K | 603.2K | 560.5K | 207.2K | 79.3K | 48.5K |
| Current liabilities | 1.04M | 2.16M | 561.8K | 1.77M | 932.4K | 1.34M | 794.4K | 373.0K | 147.4K | 126.5K |
| Total debt | 248.0K | 1.11M | 163.8K | 84.6K | 170.1K | 42.4K | ||||
| Total liabilities | 1.14M | 2.17M | 651.5K | 1.82M | 1.07M | 1.36M | 802.9K | 379.7K | 147.4K | 126.5K |
| Shareholders' equity | 3.64M | 659.9K | 867.2K | 5.87M | 7.37M | 1.71M | 1.84M | 5.85M | 8.30M | 1.42M |
| Shares outstanding | 334.2M | 269.3M | 228.3M | 221.5M | 214.4M | 185.2M | 117.9M | 117.9M | 91.2M | 117.9M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.23M | -2.92M | -6.14M | -6.96M | -6.21M | -5.40M | -2.74M | -2.94M | -1.65M | -13 |
| Capital spending | -25.8K | -23.2K | -82.3K | -99.1K | -27.0K | -68.3K | -45.5K | -110.3K | -310.8K | -10.8K |
| Free cash flow | -5.26M | -2.94M | -6.22M | -7.06M | -6.24M | -5.47M | -2.79M | -3.05M | -1.96M | -13 |
| Cash from investing | -22.8K | -583.0K | -82.3K | -99.1K | -27.0K | -68.3K | -45.5K | -110.3K | -355.8K | -355.8K |
| Cash from financing | 7.22M | 4.19M | 2.80M | 3.63M | 11.8M | 5.90M | -142.2K | -142.2K | 8.29M | 1.50M |
| Share buybacks | -536.0K | 3.50M | -117.9K | -24.2K | -467.9K | -225.1K | 0 | -750.3K | 1.50M | |
| Change in cash | 1.96M | 687.7K | -3.41M | -3.43M | 5.32M | 430.4K | -2.93M | -3.05M | 6.29M | 1.49M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Rhythm Appoints Adam Zembrzuski as Chief Commercial Officer | Nov 16, 2026 | Management or board change | ASX |
| Commercial Update-Expansion of ColoSTAT ordering capability | Nov 4, 2026 | Operations update | ASX |
| RHY Q1 FY27 Update | Nov 3, 2026 | Quarterly report | ASX |
| Quarterly Activities Report and Appendix 4C | Oct 26, 2026 | Quarterly report | ASX |
| Notice of Annual General Meeting/Proxy Form | Oct 26, 2026 | Meeting notice | ASX |
| ColoSTAT Economic Study - Australian Public Health Savings | Oct 6, 2026 | Operations update | ASX |
| Final Director's Interest Notice - Gavin Fox-Smith | Sep 30, 2026 | Ownership change notice | ASX |
| FY26 Appendix 4G and Corporate Governance Statement | Sep 29, 2026 | Annual report | ASX |
| FY26 Annual Report | Sep 29, 2026 | Annual report | ASX |
| AGM date and closing date for director nominations | Sep 28, 2026 | Meeting notice | ASX |
All 176 filings
Cap table
Built by 6ix from Rhythm Biosciences Limited’s releases
- Common shares
- 353,866,857
- Fully diluted
- 353,866,857
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 353,866,857 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 353,866,857 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Zembrzuski | Chief Commercial Officer · Since Nov 16, 2026 |
| Andrea Steele | Legal Counsel · Since at least Nov 18, 2026 |
| Carl Stubbings | Non-Executive Director · Since at least Nov 18, 2026 |
| David Atkins | Chief Executive Officer & Managing Director · Since at least Dec 22, 2025 |
| Erika Spaeth | Director of Clinical & Scientific Affairs · Since at least Jan 14, 2026 |
| Gary Goh | Director of Operations and Quality · Since at least Nov 18, 2026 |
| Maureen Baker | Non-Executive Director · Since at least Nov 18, 2026 |
| Sue MacLeman BPharm LLM MMktg FTSE | Non-Executive Interim Chair · Since at least Nov 18, 2026 |
Log in to ask 6ix AI your own questions about Rhythm Biosciences Limited.